CBDMT Announces The Invisible Revolution: White Biotechnology
From the first recombinant protein in the 70s, modern biotechnology and more particularly theindustrial or white biotechnology is a real alternative technology for the development and the production of goods from renewable resources (in 2015 up to €300 billion in chemical product sales will be bioproduced). It will allow increasing energy and processing efficiency(cost-effectiveness, flexibility, cleanness, sustainability). So please think not only about pharmaceutical products when we are talking about the 'so trendy' biotechnology market. Theinvisible white biotechnology revolution is going on.
Paris (PRWEB) February 24, 2008 -- The life science market is generally segmented in four segments:Biotechnology, Pharmaceuticals, Diagnostics and Medical Devices. A common problem is the confusion betweenthe biotechnology and pharmaceutical segments. Let us try to clarify a little bit the 'so trendy' biotechnologymarket. In fact, there are two kinds of biotechnology: the traditional and the modern biotechnologies. Thetraditional one is the fermentation mainly used in food and feed applications (Roquette, Danisco, Cargill,ADM…). The modern biotechnology comes from the discovery of recombinant DNA molecules (Stan Cohen andHerb Boyer in 1973), hybridoma technology (Cesar Milstein and Georges Kohler in 1974) and more particularlythe development of molecular biology since then.Let us go from the first biotech company to the invisiblerevolution - the white or industrial biotechnology. The first real modern biotechnology company: Genentech Inc. Genentech Inc. was founded by Herbert Boyer and Robert Swanson in 1976. One year after that, Allan Maxamand Walter Gilbert co-founded Biogen Inc. The same year (1974) Genentech reported the expression of somatostatin, the first human protein produced by a bacterium. In 1980, the first IPO, Genentech went publicOctober 14 at $35/share, raising $35 million. Within one day, the stock leaped to $89/share! The same yearAmgen Inc. was founded. One year later, in 1981 Cal Tech invented an automated gene-sequencing machine thatcan read 7,000 DNA building blocks a day. In 1982, Eli Lilly got the FDA approval to sell the first genetically engineered drug, human insulin cloned byGenentech in 1978. Ten years later, Lilly's Humulin had sales of $702 million. Then, there was the approval of the first biotech industry product, the recombinant human growth hormone (1985), followed by alpha interferonfor cancer treatment and the first genetically engineered vaccine for hepatitis B treatment (1986). In 1994,Calgene received approval to sell its FLAVR SAVER genetically engineered tomato (first GMO food). Today, the global biotechnology market is still young but currently with a value of more than $150 billion and anexpected growth of about 10 to 15% per annum. In 2007, Genentech announced financial results for the full yearwith $11.7 billion total revenue. Genentech is the second most important biotech company behind the leaderAmgen with more than $14.7 billion revenue in 2007. The biotechnology market is more and more commonly segmented by using colors to segment biotechnology